Charging Robotics Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Charging Robotics Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $775.2K | May 22, 2012 |
| FY2011 | Dec 31, 2010 | $780.1K | May 22, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $177.5K | May 22, 2012 |
| FY2011 | Dec 31, 2010 | $26.2K | May 22, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($387.0K) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($842.0K) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($804.0K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($810.0K) | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | ($17.5K) | May 17, 2023 |
| FY2021 | Dec 31, 2020 | $5.8K | Apr 18, 2022 |
| FY2011 | Dec 31, 2011 | ($1.07M) | May 22, 2012 |
| FY2011 | Aug 23, 2011 | ($1.62M) | May 22, 2012 |
| FY2011 | Dec 31, 2010 | ($2.49M) | May 22, 2012 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.90M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($777.0K) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($766.0K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($753.0K) | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | ($28.8K) | May 17, 2023 |
| FY2021 | Dec 31, 2020 | ($5.1K) | Apr 18, 2022 |
| FY2011 | Dec 31, 2011 | ($2.65M) | May 22, 2012 |
| FY2011 | Dec 31, 2010 | ($2.48M) | May 22, 2012 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $652.0K | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $319.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $329.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $682.0K | Mar 12, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.05M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($610.0K) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($644.0K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($612.0K) | Mar 12, 2024 |
| FY2021 | Dec 31, 2020 | ($5.7K) | Apr 18, 2022 |
| FY2011 | Dec 31, 2011 | ($2.34M) | May 22, 2012 |
| FY2011 | Dec 31, 2010 | ($3.10M) | May 22, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.06M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $332.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $223.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $384.0K | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | $0 | May 17, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 18, 2022 |
| FY2011 | Dec 31, 2011 | $1.57M | May 22, 2012 |
| FY2011 | Dec 31, 2010 | $1.50M | May 22, 2012 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.91M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $945.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $397.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $752.0K | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | $18.9K | May 17, 2023 |
| FY2021 | Dec 31, 2020 | $12.6K | Apr 18, 2022 |
| FY2011 | Dec 31, 2011 | $1.38M | May 22, 2012 |
| FY2011 | Dec 31, 2010 | $1.10M | May 22, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.59M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($613.0K) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($174.0K) | Apr 15, 2025 |
| FY2024 | Dec 31, 2022 | ($442.0K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $450.0K | Mar 12, 2024 |
| FY2021 | Dec 31, 2020 | ($12.6K) | May 17, 2023 |
| FY2021 | Dec 31, 2019 | ($20.5K) | Apr 18, 2022 |
| FY2011 | Dec 31, 2011 | $189.5K | May 22, 2012 |
| FY2011 | Aug 23, 2011 | $20.3K | May 22, 2012 |
| FY2011 | Dec 31, 2010 | $393.1K | May 22, 2012 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.77M | Mar 23, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.30M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($2.91M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($2.07M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($1.19M) | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | ($1.56M) | May 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.54M) | Apr 18, 2022 |
| FY2011 | Dec 31, 2011 | ($1.07M) | May 22, 2012 |
| FY2011 | Dec 31, 2010 | ($2.96M) | May 22, 2012 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $175.0K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $8.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $27.0K | Mar 12, 2024 |
| FY2011 | Dec 31, 2011 | $495 | May 22, 2012 |
| FY2011 | Dec 31, 2010 | $11.6K | May 22, 2012 |
| FY2011 | Dec 31, 2009 | $25.6K | May 22, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (30) | Mar 12, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (30) | Mar 12, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.25M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 9.56M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 9.15M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 27,273 | Mar 12, 2024 |
| FY2021 | Dec 31, 2021 | 256.74M | May 17, 2023 |
| FY2021 | Dec 31, 2020 | 36.74M | Apr 18, 2022 |
| FY2011 | Dec 31, 2011 | 12.95M | May 22, 2012 |
| FY2011 | Dec 31, 2010 | 8.00M | May 22, 2012 |